To evaluate prospectively renal function in patients with malignant germ-cell tumours (MGCTs) >10 years after retroperitoneal lymph node dissection alone (RPLND), radiotherapy alone (RAD) or different schedules of cisplatin-based chemotherapy with or without surgery/radiotherapy (CHEM).
Introduction
Modern multi-modality treatment of malignant germ-cell tumours (MGCT) cures ∼90% of patients, most of them presenting with testicular cancer (TC). According to the prevailing opinion, these young men's post-treatment life expectancy is comparable to that of age-matched males without cancer. There is, however, a growing understanding that treatment for TC may lead to long-term sequelae that not only decrease the individual patient's quality of life, but also cause life-threatening somatic morbidity. Abdominal radiotherapy of TC may cause major dyspepsia or peptic ulcer in 2-10% of patients [1, 2] and increases the risk of specific types of second cancer (upper gastrointestinal tract, bladder) [3, 4] . Several reports have claimed a raised incidence of cardiovascular risk factors after cisplatin-based chemotherapy, such as obesity and hypercholesterolemia [5] [6] [7] , besides the specific sequelae of the applied treatment: 'dry ejaculation' after retroperitoneal surgery, and ototoxicity, peripheral neuropathy and nephrotoxicity after cisplatin-based chemotherapy [7] [8] [9] [10] .
Almost all studies of renal function in TC patients have dealt with side-effects after cisplatin-based chemotherapy [7] [8] [9] 11] . Most of these investigations have demonstrated an association between renal damage and the cumulative dose of cisplatin resulting in a decreased glomerular filtration rate (GFR), and hypomagnesemia and hypophosphatemia due to tubular salt wasting [7, 11, 12] 3-5 years after chemotherapy. Petersen and Hansen [8] did not observe further decrease of GFR beyond 4 years in 22 patients examined >10 years after cisplatin-based chemotherapy. In a comparative prospective study, Aass et al. [11] showed that infradiafragmatic radiotherapy, either given alone or in addition with chemotherapy, may be nephrotoxic 3-5 years after treatment in patients treated at an age of ≥40 years, an observation that is confirmed in part by the findings of Bokemeyer et al. [7] . In discussing these results, Boyer et al. [9] emphasize that these observations require long-term follow-up with regard to eventual recovery stabilisation or worsening of the renal function. Long-term observations of renal function after routine infradiafragmatic radiotherapy of TC are, however, lacking.
The present report deals with long-term observations obtained in patients from the study by Aass et al. [11] , 13-15 years after treatment. The data were collected during 1998-2000 as part of a systematic long-term follow-up study of patients with GCT treated at the Norwegian Radium Hospital (NRH). Of particular interest were the questions of whether chemotherapy-related reduced kidney function would recover >5 years after treatment of TC, and whether routine radiotherapy for TC influenced renal function.
Patients and methods
During the period 1984 to 1988, 171 patients with newly diagnosed MGCT were prospectively evaluated with regard to their renal function before and up to 5 years after treatment. In 1998, surviving cancer-free patients from this cohort were identified and invited to undergo a new evaluation of their renal function if they were <75 years old at the scheduled outpatient visit. Due to administrative regulations of the Norwegian health care system, only patients from Southern Norway could be included in this long-term follow-up study. Furthermore, patients were excluded from the present study if they had received additional chemotherapy after 1988.
Principle management of testicular cancer
After the histological diagnosis of MGCT, in all but one patient consisting of unilateral orchiectomy, the clinical stage was determined according to the Royal Marsden staging system [13] . The present study discriminates seminoma from non-seminoma. Patients with seminoma stage I, stage IIa or limited stage IIb had abdominal radiotherapy. In the 1980s the target dose to a so-called dog-leg field [1] was 36 Gy (stage I) or 40 Gy (stage II), the daily fraction being 2 Gy applied 5 days per week. Either the posterior or anterior field was treated daily. If more than one-third of a kidney was included in the target volume, shielding of the most lateral parts of the lumbar part of the target field was performed after 20 Gy using individually adjusted lead blocks. For the purpose of the present study patients were allocated to five groups according to their treatment: Group 1 (RPLND): patients with RPLND only. Group 2 (RAD): patients whose treatment consisted of abdominal radiotherapy only. Group 3 (CH <850): patients with chemotherapy only and a cumulative dose of cisplatin <850 mg, comparable to three or four cycles of cisplatinbased chemotherapy. Group 4 (CH ≥850): patients with chemotherapy only and with a cumulative dose of cisplatin ≥850 mg. Group 5 (CH-RAD): Patients who had both cisplatin-based chemotherapy and abdominal radiotherapy, the latter either prior or after chemotherapy. For some analyses, groups 3, 4 or 5 were combined into a single chemotherapy (CHEM) group.
For nine patients in the RAD group, pre-treatment abdominal computed tomography (CT) scans were available together with the simulator images of the posterior/anterior fields and detailed documentation of the shielding procedures. Based on this information, dose volume histograms for the kidneys could be established. The median radiation doses to each of the kidneys could thus be estimated.
Assessment of renal function
Patients within the present study had their first assessment of renal function 2-3 weeks after orchiectomy/diagnosis before further treatment ('pre-treatment'). Except for group 5, the second assessment was scheduled 3 months after discontinuation of all chemotherapy. Further determinations of renal function were to be performed, respectively 1 and 3-5 years after treatment, followed by the assessment during the years 1998-2000 ('long-term').
Before 1990, renal function was assessed by 131 Iodine Hippuran clearance according to Pixberg and Just [ 14] or Oberhausen [15] . At the long-term follow-up the GFR (ml/min) was evaluated with 99 mDTPA
and blood samples [16] . Previous studies have shown that the results of Hippuran clearance are comparable to that of GFR if a correction factor of 0.20 is used [17] . Each patient's renal function was recorded as the percentage of the upper limit of the normal range of renal function related to age, sex and body surface of the individual patient. As in the previous study [11] , the lower limit of the normal range was set to 70% of this value, which is in agreement with the lower limits of the normal ranges for the used methods. 'Normal' renal function was ≥70%, whereas patients with renal function <70% were considered to have impaired renal function. In addition, the difference between the pre-treatment and longterm assessment of renal function was calculated for each patient (RFdiff). In 1984 determination of serum magnesium (Mg) was not carried out routinely in all patients with MGCT. All patients in the long-term study had serum Mg and creatinine levels determined. 
Results
A total of 85 patients from the previous prospective study had an assessment of their long-term GFR during 1998-2000 after a median observation time since diagnosis of 14 years (Table 1) .
Patients from group 5 were significantly older than the other groups both at diagnosis and at long-term follow-up (P = 0.05). Six of the patients from group 4 had received ifosfamide, and BEP 60 chemotherapy had been given to three patients from the same group. The pre-treatment mean renal function was similar in all five groups (Table 2) . At the long-term assessment, patients from groups 4 and 5 had significantly lower renal function values than those from group 1 (P = 0.03 and P = 0.003, respectively) with no difference between groups 1, 2 and 3. ANOVA also revealed a significant difference in long-term renal function between the RPLND group and the CHEM group (P = 0.004). The number of patients with impaired renal function increased from 10 at diagnosis to 25 at the long-term follow-up. A total of 11 of 53 patients from the CHEM group developed impaired renal function as compared with four of 32 patients without chemotherapy (P = 0.02). For patients from groups 3 and 4, the cumulative dose of cisplatin was associated with RFdiff ( Figure 1A ; R = 0.35, P = 0.02).
There was also a tendency towards reduced long-term renal function in the RAD group as compared with the RPLND group (P = 0.09). The analysis of the dose volume histograms revealed that in five of the nine evaluable patients, median doses of 3-4 Gy were given to the kidneys (Table 3) . Two patients had renal radiation doses of >8 Gy, the kidneys of the remaining patient receiving 5.3 Gy. No statistically significant association was observed between the renal radiation dose and the development of impaired renal function. However, the two oldest patients (numbers 265 and 2232) developed impaired renal function after their radiotherapy, whereas the renal function was normal in all nine patients before treatment. This observation is in agreement with the result of the correlation analysis: in the RAD group, age at treatment was significantly associated with RFdiff ( Figure 1B ; R = 0.54, P = 0.02). Figure 2 displays in detail the development of changes in renal function for the five treatment groups (Figure 2A ) and for the three groups, if groups 3-5 are combined ( Figure 2B ). In the RPLND group, no significant change in the pre-treatment renal function was observed during the years of follow-up. The limited number of patients in groups 4 and 5 prevents definite statements, but the relevant curves in Figure 2A do not reveal major recovery. For patients from the three chemotherapy groups combined, a significant decrease in kidney function at long-term follow-up was demonstrated (mean 14%). For the CHEM group, the mean renal function was found to already be impaired 3 months after chemotherapy, without significant recovery or further impairment thereafter. In the RAD group, the mean RFdiff was 8%, with an almost significant reduction between the pre-treatment and long-term assessment (P = 0.08). In fact, similar figures for long-term renal function were observed for the CHEM group and the RAD group. In contrast to the observations from the chemo- therapy groups, the reduction in renal function in the RAD group developed gradually, and first became detectable 3-5 years after treatment. Thereafter, no further decrease in renal function was seen. The mean serum Mg level was similar at long-term assessment in all groups. One patient in the RPLND group and two patients in CH <850 group had Mg levels below the normal range.
In the multivariate analysis, long-term impairment of renal function was predicted by age at treatment and type of treatment (Table 4) .
Discussion
Twelve to 17 years after cisplatin-based chemotherapy for MGCT renal function is significantly reduced, by a mean of 14%, related to the cumulative dose of cisplatin. After infradiafragmatic radiotherapy a tendency towards reduced renal function was observed (P = 0.08), dependent on the age of the patient at treatment.
In the present study two principally different methods for the evaluation of renal function were used, due to the change of the techniques in the laboratory during the 15 years of follow-up. While Hippuran clearance primarily assesses tubular function, GFR mainly detects glomerular dysfunction. Although previous studies from our laboratory have proven comparability of the two methods [16, 17] , this change of methods favoured reporting of our patients' renal function by relative figures (percentages) rather than absolute values (ml/ min), as is usually done. Of particular importance for the present results is the fact that an individual patient's renal function is estimated while taking into account the patient's age, thus compensating for age-related decrease in renal function. The validity and reliability of our evaluations of renal function are supported by the measurements in the RPLND group: as expected, no reduction in renal function was observed at long-term follow-up. This group therefore represented a control cohort.
Our study confirms previous observations that cisplatinbased chemotherapy leads to decrease in renal function, with the lowest renal function values obtained immediately after treatment, and with no or only slight recovery during the first 3-5 years [7, 8, 10] . Thereafter, no further improvement takes place. Even after >10 years the mean values of renal function remain decreased compared with the pre-treatment situation. Our mean decrease in renal function of 14% confirms the observation of Osanto et al. [10] , who reported a 15% reduction of creatinine clearance after five cycles of cisplatin-based chemotherapy. Our percentage of patients with impaired renal function after chemotherapy (14%) is in agreement with the range of 20-30% reported by Kollmannsberger et al. [18] , considering that 19 of our 53 patients had high cumulative cisplatin doses or had also received radiotherapy. Hypomagnesemia is a frequent finding during and immediately after cisplatin-based chemotherapy, and was also evident in 15 of 19 evaluable patients during the first year after chemotherapy (data not shown). Persisting low Mg levels have been reported repeatedly [7] . Huddart et al. [19] found, for example, low serum Mg levels in their patients examined ∼10 years after treatment. Low Mg levels after cisplatin-based chemotherapy have been associated with Raynaud phenomena, long-lasting polyneuropathy and an increased risk of myocardiac infarction. Our finding of normal post-chemotherapy serum Mg levels in the vast majority of patients are in contrast to the above observations. As loss of Mg and other electrolytes is thought to mirror a tubular dysfunction (reduced re-absorption), our finding of normalisation of Mg values thus indicates the tubular epitelium's ability to recover.
The pathogenesis of persisting cisplatin-related nephrotoxicity remains unclear. As expected, renal function impairment is most pronounced if high doses of cisplatin are given or if chemotherapy is combined with radiotherapy. Most investigators have described an association of the post-treatment renal function with the cumulative dose of cisplatin [7, 12] .
The concentration of cisplatin during the days of chemotherapy has also been discussed as a predictor of the development of reduced renal function. Except for the three patients with high-dose BEP in group 4, the serum concentrations of cisplatin during the days of chemotherapy were probably very similar in our patients whose hydration was carefully monitored during the 5-7 days of hospitalisation when chemotherapy was applied. Particularly intensive hydration regimens have been used in our patients receiving BEP 60. Under these clinical conditions the cumulative dose rather than the serum concentration of cisplatin seems to be responsible for the reduction of renal function in TC patients. If the standard dose of cisplatin (100 mg/m 2 ) is given over 2 days, as suggested by the results of a recently published large trial [20] , renal function may become more impaired, even though only three chemotherapy cycles are applied. Long-term effects of continuously elevated serum concentrations of cisplatin [21] may also, over years, reduce renal function. In this regard, clinicians should be aware that serum levels of creatinine do not sufficiently mirror the changes in renal function, as demonstrated by previous reports [7, 10, 11] and also in the present study.
Radiotherapy for early seminoma was given as two opposing infradiaphragmatic target fields, which were considered standard in the 1980s. The upper part of the target field (from the XI thoracic vertebra to the first sacral vertebra) covers the median parts of the kidneys. Such adjuvant radiotherapy is usually considered to be without severe sequelae, although the target dose of 36 Gy for stage I seminoma may today be regarded as too high. However, larger prospective studies of the long-term human renal function after radiotherapy for stage I seminoma are so far lacking. Bokemeyer et al. [7] suggested that abdominal radiotherapy may add to cisplatininduced nephrotoxicity, an observation that is confirmed in the present study. Using the above-described shielding policy of renal tissue, between 30% and 50% of each kidney could have been irradiated by 20 Gy and up to one-third of the renal tissue would have received at least 36 Gy. According to Markoe et al. [22] , the tolerability of renal tissue for fractionated radiation to the whole kidney is 20-23 Gy. This is comparable to a single fraction irradiation of 8 Gy. But even after such low doses, long-term studies in primates have shown reduction of hematocrit and increase of creatinine per body weight comparable to decreased renal function [23] . Studies in patients with abdominal irradiation due to gynecologial tumours have also shown subclinical impairment of the renal function after doses of <20 Gy to the kidneys [24] . Our data indicate that subclinical renal dysfunction may develop even though only minor volumes of the kidneys are exposed to fractionated radiation doses of <20 Gy. As also described by Dewit et al. [25] , the post-radiotherapy decrease in renal function develops gradually, and becomes detectable after 3-5 years, in agreement with late small vessel sclerosis as one possible cause for renal function impairment. Markoe et al. [22] did not observe a dose-effect relationship in their animal experiments. This is in agreement with our observations: more than the actual radiation dose received by the renal tissue, the age of the patient at treatment seems to determine the final reduction of the renal function, high age possibly impairing post-treatment recovery. The importance of age at treatment for post-irradiation impairment of renal function has also been emphasised by Irwin et al. [26] using a dose of <20 Gy. Furthermore, due to limited radiotherapy resources, only one field was exposed daily. This sub-optimal irradiation schedule may have contributed to increased renal tissue toxicity in our RAD group.
Our results on post-irradiation impairment of renal function support the current arguments to limit the use of adjuvant radiotherapy in seminoma stage I as much as possible. The application of the surveillance strategy or of one or two cycles of carboplatin may represent preferrable alternatives, whereas our data leave some doubt over whether the reduction of the target dose from 30 to 20 Gy reduces impairment of the renal function.
Twelve to 15 years after treatment renal damage remained subclinical in the patients evaluated, even though statistically significant or almost significant differences were found for the chemotherapy and radiotherapy groups. It is, however, unlikely that significant recovery will occur in the patient's lifetime. Increasing age and age-related co-morbidity may rather worsen the kidney function. The consequence is that clinicians seeing patients with TC who have had radiotherapy and/or chemotherapy, even many years after their treatment, have to consider the presence of subclinical renal damage, which in some patients may become clinically relevant during the patient's lifetime, for example during any therapy with drugs that are eliminated by the kidneys.
Our findings of persistent impaired renal function after treatment of GCT support the current treatment strategies, which avoid 'overtreatment' of this malignancy as much as possible, e.g avoiding unnecessarily prolonged chemotherapy in good prognosis patients with metastases or the current use of adjuvant radiotherapy in stage I seminoma.
